[go: up one dir, main page]

TN2010000053A1 - Derives de bi cyclolactames substitues - Google Patents

Derives de bi cyclolactames substitues

Info

Publication number
TN2010000053A1
TN2010000053A1 TNP2010000053A TN2010000053A TN2010000053A1 TN 2010000053 A1 TN2010000053 A1 TN 2010000053A1 TN P2010000053 A TNP2010000053 A TN P2010000053A TN 2010000053 A TN2010000053 A TN 2010000053A TN 2010000053 A1 TN2010000053 A1 TN 2010000053A1
Authority
TN
Tunisia
Prior art keywords
cyclolactam
derivatives
substituted
memoir
pat
Prior art date
Application number
TNP2010000053A
Other languages
English (en)
Inventor
Robert Lee Dow
Michael John Munchhof
Original Assignee
Pfizer Product Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Product Inc filed Critical Pfizer Product Inc
Publication of TN2010000053A1 publication Critical patent/TN2010000053A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention propose des composés de formule (1), et leurs sels pharmaceutiquement acceptables, formule dans laquelle R1, R2, R3, R4, R5a, R5b, R5c, R5d, Q, A, Z, et R7 répondent aux définitions figurant dans le présent mémoire; des compositions les contenant ; et leurs utilisations.
TNP2010000053A 2007-08-02 2010-01-29 Derives de bi cyclolactames substitues TN2010000053A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95350707P 2007-08-02 2007-08-02
PCT/IB2008/001963 WO2009016462A2 (fr) 2007-08-02 2008-07-22 Bicyclolactames substitués

Publications (1)

Publication Number Publication Date
TN2010000053A1 true TN2010000053A1 (fr) 2011-09-26

Family

ID=39926534

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2010000053A TN2010000053A1 (fr) 2007-08-02 2010-01-29 Derives de bi cyclolactames substitues

Country Status (34)

Country Link
US (2) US20090036425A1 (fr)
EP (1) EP2185567B1 (fr)
JP (1) JP4629808B2 (fr)
KR (1) KR20100032443A (fr)
CN (1) CN101772504A (fr)
AP (1) AP2010005163A0 (fr)
AR (1) AR067780A1 (fr)
AT (1) ATE502948T1 (fr)
AU (1) AU2008281545B2 (fr)
BR (1) BRPI0815067A2 (fr)
CA (1) CA2695291C (fr)
CL (1) CL2008002227A1 (fr)
CO (1) CO6251365A2 (fr)
CR (1) CR11223A (fr)
CY (1) CY1111628T1 (fr)
DE (1) DE602008005757D1 (fr)
DK (1) DK2185567T3 (fr)
DO (1) DOP2010000046A (fr)
EA (1) EA201000050A1 (fr)
EC (1) ECSP109932A (fr)
ES (1) ES2361716T3 (fr)
HN (1) HN2008001191A (fr)
HR (1) HRP20110335T1 (fr)
MA (1) MA31580B1 (fr)
PA (1) PA8791601A1 (fr)
PE (1) PE20090897A1 (fr)
PL (1) PL2185567T3 (fr)
PT (1) PT2185567E (fr)
SI (1) SI2185567T1 (fr)
TN (1) TN2010000053A1 (fr)
TW (1) TWI356059B (fr)
UA (1) UA94833C2 (fr)
WO (1) WO2009016462A2 (fr)
ZA (1) ZA201000255B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070087096A (ko) 2004-12-14 2007-08-27 아스트라제네카 아베 Ｄｇａｔ 억제제로서의 옥사디아졸 유도체
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
EP2004607B1 (fr) 2006-03-31 2011-10-19 Novartis AG Dérivés de l'acide (4-(4-[6-(trifluorométhyl-pyridin-3-ylamino)-N-contenant-hétéroaryl]-phényl)-cyclohexyl)-acétique et leurs applications pharmaceutiques
NZ572586A (en) 2006-05-30 2011-03-31 Astrazeneca Ab Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase
TW200808773A (en) 2006-06-23 2008-02-16 Abbott Lab Cyclopropyl amine derivatives
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
TW201038580A (en) * 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
TW201040174A (en) * 2009-02-03 2010-11-16 Pfizer 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives
EP2393811A1 (fr) * 2009-02-04 2011-12-14 Pfizer Inc. Dérivés de 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one
EP2408774B1 (fr) 2009-03-20 2014-11-26 Metabasis Therapeutics, Inc. Inhibiteurs de diacylglycérol o-acétyltransférase 1 (dgat-1) et leurs utilisations
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
JP5496409B2 (ja) 2010-03-19 2014-05-21 ファイザー・インク ２，３ジヒドロ−１ｈ−インデン−１−イル−２，７−ジアザスピロ［３．５］ノナン誘導体およびグレリン受容体のアンタゴニストまたは逆アゴニストとしてのそれらの使用
WO2011121350A1 (fr) 2010-04-01 2011-10-06 Astrazeneca Ab Inhibiteurs de dgat1 à base de 4-amino-7,8-dihydropyrimido[5,4,f][1,4]oxazépin-5(6h)-one
WO2012037258A1 (fr) 2010-09-16 2012-03-22 Abbott Laboratories Procédés de préparation de dérivés cyclopropyliques substitués en 1,2
ES2546465T3 (es) 2010-10-29 2015-09-23 Pfizer Inc Inhibidores de N1/N2-lactama acetil-CoA carboxilasa
WO2012112364A1 (fr) * 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Dérivés de lactame en tant qu'inhibiteurs de dgat-1
WO2012122075A1 (fr) * 2011-03-08 2012-09-13 Merck Sharp & Dohme Corp. Dérivés de lactame en tant qu'inhibiteurs de dgat-1
WO2012143813A1 (fr) 2011-04-22 2012-10-26 Pfizer Inc. Dérivés de pyrazolospirocétone destinés à être utilisés comme inhibiteurs d'acétyl-coa carboxylase
ES2785475T3 (es) 2011-05-10 2020-10-07 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores de canales iónicos
KR101919080B1 (ko) 2011-05-20 2018-11-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
NO3175985T3 (fr) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
CA2841757A1 (fr) 2011-07-15 2013-01-24 Etzer Darout Modulateurs de gpr 119
AU2012288493B2 (en) 2011-07-22 2015-08-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
ES2605565T3 (es) 2011-08-31 2017-03-15 Pfizer Inc Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
WO2013068439A1 (fr) * 2011-11-09 2013-05-16 Intervet International B.V. Composés 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazépine comme inhibiteurs de dgat1
MX351299B (es) 2011-11-11 2017-10-10 Pfizer 2-tiopirimidinonas.
CN104245696A (zh) * 2012-02-07 2014-12-24 凯诺斯医药公司 作为1型二酰基甘油o-酰基转移酶的抑制剂的化合物
HK1206735A1 (en) 2012-04-06 2016-01-15 辉瑞公司 Diacylglycerol acyltransferase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
IN2014MN02135A (fr) * 2012-04-25 2015-09-04 Korea Res Inst Chem Tech
WO2013164730A1 (fr) 2012-05-04 2013-11-07 Pfizer Inc. Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
BR112014031108A2 (pt) 2012-06-20 2017-06-27 Hoffmann La Roche compostos de pirazol substituído como antagonistas de lpar
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2903985A1 (fr) * 2012-10-03 2015-08-12 Advinus Therapeutics Limited Composés spirocycliques et leurs compositions et applications médicinales
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
ME03315B (fr) * 2012-11-23 2019-10-20 Glaxosmithkline Llc Nouveaux composés utilisés comme inhibiteurs de diacylglycérol acyltransférase
EP2931731A1 (fr) 2012-12-11 2015-10-21 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
JP6162820B2 (ja) 2012-12-19 2017-07-12 ファイザー・インク 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
CA2897678A1 (fr) 2013-02-13 2014-08-21 Pfizer Inc. Composes hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitues par un heteroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014140241A1 (fr) * 2013-03-15 2014-09-18 Intervet International B.V. Dérivés de pyridine en tant qu'inhibiteurs de dgat-1
CN104418866B (zh) * 2013-08-23 2018-10-16 青岛黄海制药有限责任公司 Dgat1抑制剂及其制备方法和用途
JP6348582B2 (ja) 2013-10-09 2018-06-27 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
DK3119757T3 (en) 2014-03-17 2018-06-18 Pfizer DIACYLGYLERIC-ACYL TRANSFERASE-2 INHIBITORS TO USE IN THE TREATMENT OF METABOLIC AND RELATED DISEASES
CN106458912B (zh) 2014-04-04 2020-10-27 辉瑞公司 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途
CN106459088A (zh) 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
WO2016092413A1 (fr) 2014-12-10 2016-06-16 Pfizer Inc. Composés indoliques et indazoliques qui activent l'ampk
EP3237401B1 (fr) 2014-12-22 2019-03-06 Pfizer Inc Antagonistes de récepteur ep3 de prostaglandine
CN107531647A (zh) 2015-05-05 2018-01-02 辉瑞大药厂 2‑硫代嘧啶酮类
EP3303303A1 (fr) 2015-05-29 2018-04-11 Pfizer Inc Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de l'enzyme vanine-1
PT3766885T (pt) 2015-06-17 2022-08-09 Pfizer Compostos tricíclicos e a sua utilização como inibidores de fosfodiesterase
WO2016203335A1 (fr) 2015-06-18 2016-12-22 Pfizer Inc. Nouvelles pyrido [2,3-b] pyrazinones utilisées en tant qu'inhibiteurs de bromodomaines de la famille bet
CA2995153A1 (fr) 2015-08-13 2017-02-16 Pfizer Inc. Composes aryle ou heteroaryle condenses bicycliques
DK3341367T3 (da) 2015-08-27 2021-04-12 Pfizer Bicyklisk-fusionerede heteroaryl- eller arylforbindelser som irak4-modulatorer
WO2017037567A1 (fr) 2015-09-03 2017-03-09 Pfizer Inc. Régulateurs de la frataxine
WO2017051303A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. Dérivés de tétrahydropyrano[3,4-d] [1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
AU2016325665A1 (en) 2015-09-24 2018-03-08 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
WO2017051294A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides utiles comme inhibiteurs de bace
US9809579B2 (en) 2015-12-29 2017-11-07 Pfizer Inc. Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
US10906888B2 (en) 2016-07-14 2021-02-02 Pfizer Inc. Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN108164548B (zh) * 2016-12-07 2020-09-08 四川大学 嘧啶并吗啉衍生物及其制备方法和用途
WO2019133445A1 (fr) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1
TWI718644B (zh) 2018-08-31 2021-02-11 美商輝瑞股份有限公司 用於治療ｎａｓｈ／ｎａｆｌｄ和相關疾病之組合
WO2020102575A1 (fr) 2018-11-16 2020-05-22 Inception Ibd, Inc. Aminothiazoles hétérocycliques et leurs utilisations
EP3972596B1 (fr) 2019-05-20 2025-07-16 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
JP7498199B2 (ja) 2019-06-28 2024-06-11 ファイザー・インク 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
HUE068174T2 (hu) 2020-02-07 2024-12-28 Gasherbrum Bio Inc Heterociklusos GLP-1 agonisták
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
US20250066337A1 (en) 2021-08-26 2025-02-27 Pfizer Inc. Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide
KR20240110881A (ko) 2021-12-01 2024-07-16 화이자 인코포레이티드 당뇨병, 신장 질환, nash 및 심부전의 치료를 위한 분지쇄 알파 케토산 데하이드로게나제 키나제 억제제로서 3-페닐-1-벤조티오펜-2-카복실산 유도체
EP4508047A1 (fr) 2022-04-14 2025-02-19 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
IL319486A (en) 2022-10-07 2025-05-01 Pfizer HSD17B13 Inhibitors and/or Retarders
WO2024118524A1 (fr) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase
AU2023396387A1 (en) 2022-12-15 2025-06-26 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
AU2023393326A1 (en) 2022-12-16 2025-06-19 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100887471B1 (ko) * 2002-01-18 2009-03-10 교린 세이야꾸 가부시키 가이샤 축합 바이사이클릭 피리미딘 유도체
CA2514473C (fr) * 2002-11-22 2008-05-27 Japan Tobacco Inc. Heterocycles contenant de l'azote bicyclique fusionne
CA2554455A1 (fr) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorexigene
JP2006056881A (ja) * 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
US7749997B2 (en) * 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors

Also Published As

Publication number Publication date
ECSP109932A (es) 2010-03-31
MA31580B1 (fr) 2010-08-02
UA94833C2 (en) 2011-06-10
ZA201000255B (en) 2011-03-30
US20090036425A1 (en) 2009-02-05
PA8791601A1 (es) 2009-12-16
HN2008001191A (es) 2012-01-17
JP2010535190A (ja) 2010-11-18
CY1111628T1 (el) 2015-10-07
TWI356059B (en) 2012-01-11
CL2008002227A1 (es) 2009-04-17
WO2009016462A2 (fr) 2009-02-05
BRPI0815067A2 (pt) 2015-02-10
KR20100032443A (ko) 2010-03-25
DOP2010000046A (es) 2010-03-31
JP4629808B2 (ja) 2011-02-09
HRP20110335T1 (hr) 2011-06-30
PL2185567T3 (pl) 2011-07-29
CO6251365A2 (es) 2011-02-21
CA2695291C (fr) 2012-04-17
EP2185567B1 (fr) 2011-03-23
CR11223A (es) 2010-02-04
AU2008281545B2 (en) 2011-12-08
SI2185567T1 (sl) 2011-06-30
WO2009016462A3 (fr) 2009-03-26
PT2185567E (pt) 2011-05-27
US20090137551A1 (en) 2009-05-28
DE602008005757D1 (de) 2011-05-05
ES2361716T3 (es) 2011-06-21
ATE502948T1 (de) 2011-04-15
AU2008281545A1 (en) 2009-02-05
AR067780A1 (es) 2009-10-21
PE20090897A1 (es) 2009-08-06
US7718645B2 (en) 2010-05-18
CA2695291A1 (fr) 2009-02-05
EA201000050A1 (ru) 2010-08-30
CN101772504A (zh) 2010-07-07
AP2010005163A0 (en) 2010-02-28
TW200916471A (en) 2009-04-16
EP2185567A2 (fr) 2010-05-19
DK2185567T3 (da) 2011-05-16

Similar Documents

Publication Publication Date Title
TN2010000053A1 (fr) Derives de bi cyclolactames substitues
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
GEP20094736B (en) Prodrugs of piperazine and substituted piperidine antiviral agents
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
MA31419B1 (fr) Derives de pyridine
PE20090705A1 (es) Derivados de uracilo en el tratamiento de hepatitis c
ECSP088549A (es) Nuevos derivados de pirrol fusionado
ECSP088812A (es) Derivados de dihidropirazolopirimidinona
MX2010000658A (es) Derivados de pirimidina 934.
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
TNSN07022A1 (fr) Derives de pyridine
PE20080093A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
ATE369370T1 (de) Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
AR065280A1 (es) Agentes antiparasitarios
TNSN06186A1 (fr) Pyrido [2,3-d] pyrimidine -2, 4-diamines servant d'inhibiteurs de pde 2
MA27040A1 (fr) Nucleosides substitues en 4'
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
CY1109441T1 (el) Ενδιαμεσα προϊοντα για την παραγωγη διοξανιου-2-αλκυλκαρβαμικου
MY140841A (en) Indozolone derivatives as 11b-hsd1 inhibitors
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
CO6190626A2 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
MA29926B1 (fr) Derives de pyrazine